HUE028594T2 - Cardiovascularis betegség diagnózisa - Google Patents
Cardiovascularis betegség diagnózisa Download PDFInfo
- Publication number
- HUE028594T2 HUE028594T2 HUE12152464A HUE12152464A HUE028594T2 HU E028594 T2 HUE028594 T2 HU E028594T2 HU E12152464 A HUE12152464 A HU E12152464A HU E12152464 A HUE12152464 A HU E12152464A HU E028594 T2 HUE028594 T2 HU E028594T2
- Authority
- HU
- Hungary
- Prior art keywords
- subject
- level
- bnp
- levels
- bmi
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (5)
- SZABÁSA LMÍ IGÉN V PONTOK 1. 7« vitro éprás cárdiovasoolads betegség tCVÖj diagnosztizálására alanyban, a7cîï#|; tsd^beg Ittbésé (8MÍ) pagyobb vagy egyen!« |$-séS. vagy károsodott vesefunkciója vsa, gltti az e|Äi tartalmazza: az alany testtömeg indexének (BMÎ) kiválasztását ésijta az álasy BMSide nagyobb vagy «gyeseié 2S-tsél, m alany kíválasztássk vsgy az alany vasefenkdé|áasfc értékelését és na M alanynak károsodott Yesa:pifeiója vsa, áli$r az alany y választását; és: Bttlpaá pítóörstíkaá g$p(ü (BM*> Is itteftebkín 1 mesgttoNszerf I pT2) megPtátöziSÉis kiválasztott: slatty biótogia! onntálában: afeo! az alany BNP szltti|d Is Oldható ST2 szsnfe Riaħ&, bogy m alanynak van-e C¥D-ja.
- 2. Az I. Igénypont &zennf elárás, alól a CVD szlvellgíelttttssg: va^- tSdpmhöMa, iá, Az 1. ;igéöy|ttttlt;SkéfiÉI d||rás, sittől az alpynak dpgsoep vagy meM&pakm van,
- 4, Az 1. Igêbypont szeriatt e|árág, api m oÄato MB szintje meg van határozva rendelkezésre álláskofs vagy lyf nappai a sadist féllépte mánmalanyóam
- 5. Az I, igénypont szerinti ejjáráa, amely iovabêâ íam&nazza az alanyban agy vagy iösh másik biomarker szint megpíározasát, amelyek opcionálisan. ki vasnak válaszig a következőkből álló éSöpottbói: 'N-vegő pto-aînalls saídatadkas pepiM fjNTkproANP), atdails: saMarettkas pepiid jANF). irnfSSÄ, C-reaktlv :PeÄfei». vdir ifcaÖKsmM nitrogén éBíTMk nïâj&mkeiè enzimek, albtsnm. és bakteriális endotoxin. & Az t, igénypont szerinti. eljárás, apt annák. tóeglsíttározása, bogy az alanynak vanm káensodott veseörnkelöilk lartalrnazm a glnamralám fttrádós ssbesség (GFR) éSÁagy széf«® kröätiÄ színi: megbáiároa&Sát és az alanynak károsodott yesaípkeicp van. ka GFR-jPk vagy sz^aíni kZsálíbsn iSzfeijttk a kövéikezö .táblázat szerinti:%. Az 1. igénypont szerinti eljárás, Sböl az alanynak károsodott y«sefonk.dójs van,, lia GFR-jSk kisebb, mnl 50 ujjperc».
- 8.. Az I. igénypont szedőit éjjálás, ahol az alanynak ΒΚΒφ nagyobb vagy egyenlő PMïâ! zagy az alany BMI-je 3 25*29 tmomnányhan va®, Ő, Az L igénypont szeemtj e jjMs, %mW' *®?#M iartaltttszza a IldMzlkplÖ vagy szivfettkéip őzikéi mérését. id. Az I. Igénypont szerinti eljárás, ahol a BNF szint és az oldható ST2 szint vért, plazmát vagy szérumot tartalmazó biológiai mintában vannak detektál«».
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79691206P | 2006-05-01 | 2006-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028594T2 true HUE028594T2 (hu) | 2016-12-28 |
Family
ID=38668487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12152464A HUE028594T2 (hu) | 2006-05-01 | 2007-05-01 | Cardiovascularis betegség diagnózisa |
Country Status (13)
Country | Link |
---|---|
US (2) | US10203339B2 (hu) |
EP (3) | EP2021796B1 (hu) |
JP (5) | JP5377289B2 (hu) |
AT (1) | ATE545032T1 (hu) |
AU (1) | AU2007248160B2 (hu) |
CA (1) | CA2650963C (hu) |
DK (2) | DK2482078T3 (hu) |
ES (2) | ES2566169T3 (hu) |
HU (1) | HUE028594T2 (hu) |
PL (2) | PL2482078T3 (hu) |
PT (1) | PT2021796E (hu) |
SI (1) | SI2482078T1 (hu) |
WO (1) | WO2007130962A2 (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
WO2003094856A2 (en) | 2002-05-09 | 2003-11-20 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
US7998683B2 (en) | 2006-04-24 | 2011-08-16 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
EP2021799B1 (en) * | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
EP2021796B1 (en) | 2006-05-01 | 2012-02-08 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
PT2019965E (pt) * | 2006-05-02 | 2015-08-28 | Critical Care Diagnostics Inc | Diagnóstico diferencial entre doença pulmonar e cardiovascular |
ES2663662T3 (es) | 2008-01-18 | 2018-04-16 | President And Fellows Of Harvard College | Métodos para detectar distintivos de enfermedades o afecciones en fluidos corporales |
WO2009129454A2 (en) * | 2008-04-18 | 2009-10-22 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
JP2011530705A (ja) * | 2008-08-13 | 2011-12-22 | エフ.ホフマン−ラ ロシュ アーゲー | 肺塞栓症のためのDダイマー、トロポニン、NT−proBNP |
EP2336740B1 (en) * | 2009-12-10 | 2014-02-12 | Emhart Glass S.A. | Method and system for monitoring a glass container forming process |
US9671357B2 (en) | 2009-12-10 | 2017-06-06 | Emhardt Glass S.A. | System and method for monitoring hot glass containers to enhance their quality and control the forming process |
EP3848394A1 (en) | 2010-04-09 | 2021-07-14 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
SG10201505724SA (en) | 2010-07-23 | 2015-09-29 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
US20130184178A1 (en) | 2010-07-23 | 2013-07-18 | President And Fellows Of Harvard College | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions |
WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
WO2012012709A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting cardiovascular diseases or conditions |
SG10201505723UA (en) | 2010-07-23 | 2015-09-29 | Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
WO2012025633A1 (en) * | 2010-08-27 | 2012-03-01 | University Of Zurich | A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
BR112014001283A2 (pt) | 2011-07-18 | 2017-02-21 | Critical Care Diagnostics Inc | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
WO2013022760A1 (en) * | 2011-08-05 | 2013-02-14 | Alere San Diego, Inc. | Methods and compositions for monitoring heart failure |
EP3434260A1 (en) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
CN104603289A (zh) | 2012-06-15 | 2015-05-06 | 哈里·斯泰利 | 检测疾病或病状的方法 |
SG10201610537VA (en) | 2012-06-15 | 2017-02-27 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
RU2683026C2 (ru) | 2012-08-16 | 2019-03-26 | Критикал Кэа Дайэгностикс, Инк. | Способы прогнозирования риска развития гипертензии |
CN104737170A (zh) * | 2012-08-21 | 2015-06-24 | 重症监护诊断股份有限公司 | 多标记风险分层 |
EP2931060B1 (en) * | 2012-12-14 | 2017-09-06 | Hill's Pet Nutrition, Inc. | Anti-aging foods for companion animals |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
WO2014164366A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting cancer |
CN106461636A (zh) | 2014-01-10 | 2017-02-22 | 重症监护诊断股份有限公司 | 用于测定心力衰竭风险的方法和*** |
WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3012A (en) * | 1843-03-21 | Machine fob | ||
US4004A (en) * | 1845-04-16 | Wooden bbidge | ||
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | hBNPのC端を認識するモノクロ−ナル抗体 |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
JP2732005B2 (ja) | 1992-12-14 | 1998-03-25 | 眞一 富永 | ヒトst2をコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法 |
JPH0731479A (ja) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | マウスst2lをコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法 |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
EP0963205A4 (en) | 1996-08-23 | 2002-10-02 | Human Genome Sciences Inc | T1 RECEPTOR TYPE LIGAND II |
CA2282401A1 (en) | 1997-02-28 | 1998-09-03 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
DE19711932A1 (de) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms |
PT1003501E (pt) | 1997-04-02 | 2005-07-29 | Brigham & Womens Hospital | Utilizacao de um agente para reduzir o risco de doencas cardiovasculares |
US6210976B1 (en) | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
DK1016867T3 (da) | 1997-09-11 | 2006-05-22 | Shionogi & Co | Fremgangsmåde til immunassay af BNP |
US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
EP1140137A2 (en) | 1998-12-18 | 2001-10-10 | Scios Inc. | Method for detection and use of differentially expressed genes in disease states |
WO2000073498A1 (en) | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
FR2795823B1 (fr) * | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
WO2002016416A2 (en) | 2000-08-22 | 2002-02-28 | The Brigham And Women's Hospital, Inc. | Diagnosis and treatment of cardiovascular conditions |
AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
ATE458199T1 (de) * | 2001-05-04 | 2010-03-15 | Biosite Inc | Diagnostische marker der akuten koronaren syndrome und ihre verwendungen |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
WO2003094856A2 (en) | 2002-05-09 | 2003-11-20 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
WO2003100000A2 (en) | 2002-05-24 | 2003-12-04 | Tularik Inc. | Amplification and overexpression of oncogenes |
US8263325B2 (en) | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
WO2004046722A2 (de) * | 2002-11-16 | 2004-06-03 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
WO2004056868A2 (en) | 2002-12-19 | 2004-07-08 | Endocube Sas | Nf-hev compositions and methods of use |
US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
US20050250156A1 (en) | 2003-10-31 | 2005-11-10 | Shebuski Ronald J | Detection of acute myocardial infarction biomarkers |
EP2386657B1 (en) | 2003-11-26 | 2014-01-08 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
AU2004296829A1 (en) | 2003-12-05 | 2005-06-23 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
EP1986012B1 (en) | 2005-01-24 | 2012-06-06 | F. Hoffmann-La Roche AG | The use of Bnp-type peptides for assessing the risk of suffering from heart failure as a consequence of volume overload |
EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのadamts13の測定と利用 |
US7998683B2 (en) | 2006-04-24 | 2011-08-16 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
EP2021799B1 (en) | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
EP2021796B1 (en) | 2006-05-01 | 2012-02-08 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
PT2019965E (pt) | 2006-05-02 | 2015-08-28 | Critical Care Diagnostics Inc | Diagnóstico diferencial entre doença pulmonar e cardiovascular |
WO2007130627A2 (en) | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
EP2158330A2 (en) | 2007-05-11 | 2010-03-03 | Tufts Medical Center | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
WO2009040133A1 (en) | 2007-09-26 | 2009-04-02 | Universitätsklinikum Heidelberg | Osteopontin as novel prognostic biomarker for heart failure |
FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
WO2009129454A2 (en) | 2008-04-18 | 2009-10-22 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
CN102317790B (zh) | 2008-11-11 | 2014-12-10 | B.R.A.H.M.S有限公司 | Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用 |
WO2011060361A1 (en) | 2009-11-13 | 2011-05-19 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
EP3848394A1 (en) | 2010-04-09 | 2021-07-14 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
BR112014001283A2 (pt) | 2011-07-18 | 2017-02-21 | Critical Care Diagnostics Inc | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
EP3434260A1 (en) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
RU2683026C2 (ru) | 2012-08-16 | 2019-03-26 | Критикал Кэа Дайэгностикс, Инк. | Способы прогнозирования риска развития гипертензии |
CN104737170A (zh) | 2012-08-21 | 2015-06-24 | 重症监护诊断股份有限公司 | 多标记风险分层 |
CN106461636A (zh) | 2014-01-10 | 2017-02-22 | 重症监护诊断股份有限公司 | 用于测定心力衰竭风险的方法和*** |
US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2007
- 2007-05-01 EP EP07761666A patent/EP2021796B1/en not_active Not-in-force
- 2007-05-01 CA CA2650963A patent/CA2650963C/en not_active Expired - Fee Related
- 2007-05-01 SI SI200731749A patent/SI2482078T1/sl unknown
- 2007-05-01 WO PCT/US2007/067914 patent/WO2007130962A2/en active Application Filing
- 2007-05-01 DK DK12152464.9T patent/DK2482078T3/en active
- 2007-05-01 PT PT07761666T patent/PT2021796E/pt unknown
- 2007-05-01 AU AU2007248160A patent/AU2007248160B2/en not_active Ceased
- 2007-05-01 PL PL12152464T patent/PL2482078T3/pl unknown
- 2007-05-01 ES ES12152464.9T patent/ES2566169T3/es active Active
- 2007-05-01 EP EP15198075.2A patent/EP3059594A1/en not_active Withdrawn
- 2007-05-01 HU HUE12152464A patent/HUE028594T2/hu unknown
- 2007-05-01 AT AT07761666T patent/ATE545032T1/de active
- 2007-05-01 US US12/299,177 patent/US10203339B2/en active Active
- 2007-05-01 ES ES07761666T patent/ES2380711T3/es active Active
- 2007-05-01 DK DK07761666.2T patent/DK2021796T3/da active
- 2007-05-01 PL PL07761666T patent/PL2021796T3/pl unknown
- 2007-05-01 JP JP2009510021A patent/JP5377289B2/ja not_active Expired - Fee Related
- 2007-05-01 EP EP12152464.9A patent/EP2482078B1/en not_active Not-in-force
-
2012
- 2012-04-26 JP JP2012101238A patent/JP5467120B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-27 JP JP2014012149A patent/JP5676789B2/ja not_active Expired - Fee Related
- 2014-12-25 JP JP2014261824A patent/JP6008933B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-13 JP JP2016178188A patent/JP6470717B2/ja not_active Expired - Fee Related
-
2018
- 2018-12-17 US US16/221,673 patent/US20190120852A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6470717B2 (ja) | 心血管疾患の診断方法 | |
EP2021799B1 (en) | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease | |
DK2019965T3 (en) | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease | |
WO2009040133A1 (en) | Osteopontin as novel prognostic biomarker for heart failure | |
JP2021170021A (ja) | 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法 | |
AU2016201172B2 (en) | Diagnosis of cardiovascular disease | |
WO2022221264A1 (en) | Methods and compositions for analysis of acute kidney injury |